Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, September 2000, p. 2458-2464, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Ofloxacin-Loaded Liposomes: In Vitro Activity and
Drug Accumulation in Bacteria
Pio M.
Furneri,1,*
Massimo
Fresta,2
Giovanni
Puglisi,2 and
Gianna
Tempera1
Department of Microbiological
Sciences1 and Department of
Pharmaceutical Sciences,2 University of
Catania, Catania, Italy
Received 22 December 1999/Returned for modification 28 March
2000/Accepted 20 June 2000
 |
ABSTRACT |
Different ofloxacin-loaded unilamellar vesicles were prepared by
the extrusion technique, and their antimicrobial activities were
determined in comparison to those of the free drug by means of MIC
determinations with both American Type Culture Collection standards and
wild-type bacterial strains (six strains of Enterococcus faecalis, seven strains of Escherichia coli, six
strains of Staphylococcus aureus, and six strains of
Pseudomonas aeruginosa). The accumulation of
ofloxacin and liposome-ofloxacin was measured by determining the amount
of the drug inside the bacteria as a function of time. Encapsulated
fluoroquinolone yielded MICs which were at least twofold lower than
those obtained with the free drug. In particular, liposomes made up of
dimyristoylphosphatidylcholine-cholesterol-dipalmitoylphosphatidylserine and dimyristoylphosphatidylcholine-cholesterol-dihexadecylphosphate (4:3:4 molar ratio) provided the best improvement in antimicrobial activity against the various bacterial strains investigated. The liposome formulation produced higher intracellular fluoroquinolone concentrations than those achieved simultaneously with the free drug in
both E. coli and P. aeruginosa.
 |
INTRODUCTION |
Since the discovery of the original
DNA gyrase inhibitor nalidixic acid, numerous structural modifications
have been carried out to the quinolone nucleus to increase
antimicrobial activity and improve pharmacokinetic performance
(12, 22, 29, 46).
The efficacy of fluoroquinolone antibiotics has led to their proposed
use for the treatment and prophylaxis of different bacterial diseases:
therapy for the respiratory tract, skin structure, and bone and
gastrointestinal infections, as well as urinary tract infections
(20, 21, 23, 36, 41). However, many studies were developed
to improve the potency and spectrum, to achieve sustained blood levels,
and to reduce as much as possible drug interactions with various
metabolic pathways and physiological processes. Particularly, the use
of antibiotic "carrier/delivery systems" would result in enhanced
concentrations of the antimicrobial agent at the site of infection. In
fact, delivery systems can contribute to (i) targeting of the drug to
the infected tissues, (ii) increasing intracellular antibiotic
concentrations, and (iii) reducing toxicity of potentially toxic drugs
resulting from the targeting to the infectious organisms.
Liposomes are possible carriers for controlled drug delivery and
targeting by the intravenous route. As with most drug carriers, liposomes have been extensively used in an attempt to improve the
selective delivery and the therapeutic index of antimicrobial agents
(3, 47). Liposomes, artificial phospholipid membranes, are
usually produced from naturally occurring, biodegradable, and nontoxic
lipids, such as lecithin, cholesterol, and phosphatidylserine.
The aim of the study described here was to investigate the
antimicrobial activity against and accumulation in bacteria of ofloxacin-loaded liposomes (of different lipid compositions) in comparison to those of free drugs. Our preliminary experiments demonstrated that ofloxacin-loaded liposomes showed an antibacterial activity that was the same as or better than that of the free drug
(45). Moreover, the liposome formulation was able to deliver ofloxacin into McCoy cells in a greater amount (2.6-fold) than the free
drug, improving antibiotic accumulation (16).
 |
MATERIALS AND METHODS |
Chemicals.
Dipalmitoyl-DL-
-phosphatidyl-L-serine (PS),
cholesterol (Chol), lipopolysaccharide (LPS) obtained by
trichloroacetic acid extraction, and
L-
-phosphatidyl-DL-glycerol (PG) were
obtained from Sigma Chemical Co. (St. Louis, Mo.). Dihexadecyl hydrogen phosphate (DP), 1,2-dimyristoyl-sn-glycero-phosphocholine
monohydrate (MC),
1,2-dipalmitoyl-sn-glycero-phosphoethanolamine (PE),
1,2-dipalmitoyl-sn-glycero-phosphatidic acid sodium salt
(PA), dipicolinic acid (DPA; pyridine-2,6-dicarboxylic acid), and
terbium(III) chloride were obtained from Fluka Chemical Co. (Buchs,
Switzerland). Before use, the lipid purity (greater than 99%) was
assayed by two-dimensional thin-layer chromatography on silica gel
plates (E. Merck, Darmstadt, Germany) (14). Ofloxacin was a
gift from Sigma-Tau S.p.A. (Pomezia, Italy). The purity of the drug was
greater than 99.5%, as assayed by high-performance liquid
chromatography (HPLC) analysis. Double-distilled water was used
throughout. All other materials and solvents (Carlo Erba, Milano,
Italy) were of analytical grade.
Strains.
Escherichia coli ATCC 25922, E. coli ATCC 35218, Enterococcus faecalis ATCC 29212, Staphylococcus aureus ATCC 29213, Pseudomonas aeruginosa ATCC 27853, and 20 recent clinical isolates (5 strains of E. faecalis, 5 strains of E. coli, 5 strains
of S. aureus, and 5 strains of P. aeruginosa
resistant to quinolones) were investigated for this study.
Liposome preparation.
The desired amount (50 mg) of lipid
components of the liposome matrix were solubilized in chloroform (5 ml)
in a round-bottom flask in the presence of 10 g of glass beads
(mean diameter, 2 to 3 mm) (Carlo Erba). The organic solvent was
evaporated off at 30°C on a rotating evaporator under a nitrogen
stream and stored overnight under high vacuum to form a thin lipid film
to be deposited on the inner wall of glass vials and on the glass bead
surface. Liposomes were prepared by dispersing the lipid component
films of the various liposomal formulations in an isotonic phosphate buffer solution (1 ml) containing ofloxacin (20 mg). This procedure was
carried out at 55°C under mechanical stirring. The liposome suspension was submitted to 10 cycles of freezing (liquid nitrogen) and
thawing (40°C in a water bath) and was then extruded through two
(stacked) polycarbonate membranes (diameter, 25 mm; Nucleopore Corp.,
Pleasanton, Calif.) at 50°C at a pressure of 4,100 kPa. For the
extrusion, a stainless steel extrusion device (Lipex Biomembranes, Vancouver, British Columbia, Canada) was used (13). To
obtain small unilamellar vesicles, the extrusion procedure used
consisted of 10 passages through 400-nm-pore-size filters, followed by
another cycle of 10 passages through 200-nm-pore-size membrane filters. Different unilamellar liposome formulations were prepared. Liposomes were made up of MC, Chol, and a charged phospholipid (PS, DP, PE, or
PA) at a molar ratio of 4:3:4, respectively.
The untrapped drug was separated from the liposome colloidal suspension
by gel permeation chromatography, as previously described (16). Liposome drug loading was evaluated by HPLC analysis
(32), after destruction of the vesicular carrier with a
mixture of methanol-acetonitrile (8:2 [vol/vol]). Results are
expressed as drug content and encapsulation capacity (5).
The encapsulation parameter, which is defined as the encapsulation
capacity (milliliters/millimoles), is a function of the liposome size
and the number of lamellae per vesicle. The encapsulation capacity is
calculated as follows: encapsulation capacity = Cf/(C0 × C1), where C0 is the initial
drug concentration, Cf is the final drug
concentration, and C1 is the lipid concentration in the liposome suspension. The various concentrations are expressed as
millimoles/milliliter. The drug content depends on the encapsulation capacity and on the lipid concentration in the vesicles. This parameter
is calculated as follows: drug content = [D1/(D1 × L1)] × 100, where D1 is the amount of drug found
in the liposomes and L1 is the amount of
liposome lipids.
Morphological characterization of liposomes.
Photon
correlation spectroscopy (PCS) (Zetamaster; Malvern Instruments Ltd.,
Sparing Lane South, Worcestershire, England) was used to determine the
vesicle size. The experiments were carried out using a solid-state
laser as a light source. The laser was a nominal 4.5-mW laser diode
with a maximum output of 5 mW at 670 nm. The PCS measurements were
carried out at a scattering angle of 90°. The correlation functions
were performed by a Malvern PCS submicron particle analyzer and a
third-order cumulant fitting (6, 11) with a dilation of 1.20 to obtain the mean diameter and polydispersity. In particular, the
polydispersity index gives information on the size distribution of the
colloidal sample; values lower than 0.3 are attributed to a narrow size
distribution, and the lower the value the more homogeneous the
colloidal population. The real and imaginary refractive indexes were
set at 1.59 and 0.0, respectively. The following parameters were used
for experiments: medium refractive index, 1.330; medium viscosity, 1.0, and dielectric constant, 79. The samples were suitably diluted with
filtered water (Sartorius membrane filters, 0.22-µm pore size) to
avoid multiscattering phenomena and were placed in a quartz cuvette. Thirty measurements were obtained for each sample.
The morphological characterization was carried out by freeze-fracture
electron microscopy using the propane-jet technique (35).
The samples were fractured at
165°C, and platinum-carbon replicas
were observed in a Philips EM 301 electron microscope at 100 kV.
The liposome lamellarity was evaluated by 31P-nuclear
magnetic resonance (31P-NMR) spectroscopy (49).
Mn2+ was added to the vesicle colloidal suspension (2 ml;
50 µmol of phospholipid per ml in an NMR tube) at levels high enough
(5 mM) to eliminate the 31P-NMR signal arising from those
phospholipids facing the external medium. Proton-decoupled
31P-NMR spectra were obtained with a GN500 MHz spectrometer
operating at 202.45 MHz. Trimethyl phosphate (10% in D2O)
was used as a reference and set at 0.0 ppm. The average number of
bilayers (N) was calculated from the following expression: N = 100/(2 × RLOS), where RLOS is the percentage of the relative loss
of signal found before and after Mn2+ addition
(18).
Vesicle fusion experiments.
The fusogenic properties of the
various liposome formulations were investigated by means of assays for
mixing aqueous vesicle contents by using MC-PG-LPS (5:3:2 molar ratio)
vesicles as a model system of bacterial outer membranes
(53). This kind of study is based on the interaction between
Tb(III) and DPA forming the fluorescent
Tb(DPA)33
complex (51). The
fluorescence intensity of Tb(III) in aqueous solution on its own was
very low (4, 51), whereas it became higher, up to
104-fold, following the interaction with DPA
(55). In order to evaluate the fusogenic properties, Tb(III)
was encapsulated in MC-PG-LPS vesicles, and DPA in liposomes was made
up of various phospholipid mixtures. The complex
Tb(DPA)33
was excited at 276 nm, and the
emission fluorescence was measured at 492 and 554 nm. Tb(III)-loaded
vesicles were prepared in the presence of 2.5 mM TbCl3 and
50 mM sodium citrate, following the freeze-and-thaw procedure, and then
extruded through 1.2-µm-pore-size membranes, as described above.
Liposomes (mean diameter, 200 nm) made up of various phospholipid
mixtures were prepared in the presence of 50 mM DPA. The free probe
molecules were removed by gel-permeation chromatography. The
fluorescence intensity of the various vesicles with entrapped DPA or
Tb(III) was measured after making a 1:5 dilution with isotonic
phosphate buffer to avoid fluorescence quenching (
ex,
276 nm). The fluorescence data represent the measured fluorescence
intensity divided by the fluorescence intensity obtained after complete
release of the vesicle-entrapped components following cholate addition
(to yield a 3% [wt/vol] concentration). Experiments were carried out
at 37 ± 0.05°C (Haake F3-R).
Susceptibility test procedure.
The antimicrobial activity of
ofloxacin-loaded liposomes was determined in comparison with that of
the free drug, with MICs determined by using the standard broth
microdilution assay (37). The liposome suspension containing
ofloxacin was added in order to obtain an equivalent drug concentration
with respect to that of the free drug solution, thus making the direct
comparison of the results possible to evaluate the effectiveness of the
liposome carrier. Mueller-Hinton broth was replaced by Iso-Sensitest
broth (Oxoid, Basingstoke, United Kingdom) as previously described
(45). Stock solutions of liposomo-ofloxacin (2,560 µg/ml
in Iso-Senstitest broth) and ofloxacin (512 µg/ml in Iso-Sensitest
from an original stock in water at 5,120 µg/ml) were prepared and
diluted as proposed by National Committee for Clinical Laboratory
Standards (37). A total of 11 concentrations of each sample
were prepared. A suspension of organisms (1 µl of a suspension
containing 107 CFU/ml) was added to each well. A positive
control (growth) consisting of organisms in broth, a negative control
(sterility) consisting of uninoculated broth, drug control consisting
of broth containing the highest concentrations of drug, and drug-free
liposomes (concentrations 1, 10, and 100 times higher than those used
throughout the experiments) were included for each bacterial strain
tested. Plates were sealed with transparent acetate and incubated at
37°C under atmospheric conditions for up to 18 h. Each assay was
repeated six times with each antimicrobial agent formulation and six
additional times on a different day with all formulations to ensure
reproducibility of results.
Drug uptake.
The accumulation of ofloxacin and
ofloxacin-loaded liposomes was measured as previously described by us
(15), by a method derived from those described by Chapman
and Georgopapadakou (10), Mortimer and Piddock
(34), and Asuquo and Piddock (2). In the same way
as for the susceptibility test, the amount of ofloxacin added to the
bacterial cell suspensions as free drug or entrapped within liposomes
was equal. E. coli was grown in Iso-Sensitest broth with
shaking at 37°C up to an optical density of 0.8 at 660 nm, while
P. aeruginosa was grown in the same conditions, but at
35°C and up to an optical density of 0.65 at 470 nm (2, 34). Bacteria were harvested by centrifugation at
4,470 × g for 10 min at 20°C. For E. coli, the pellet was resuspended in 50 mM cold sodium phosphate
buffer (pH 7.0), washed, and concentrated 20-fold in the same buffer.
For P. aeruginosa, the pellet was resuspended in 30 mM cold
sodium phosphate buffer (pH 7.0) containing 5% glucose, washed, and
concentrated 20-fold in the same buffer (2, 15, 34).
Aliquots of 15 ml were poured into a sterile bottle containing a stir
bar and allowed to equilibrate at 37°C in a water bath on a magnetic
stirrer for 10 min. A zero-time sample for each strain was removed, and
the two formulations of ofloxacin were added to yield a final
concentration of 10 µg/ml. At predetermined intervals, 0.5 ml of the
solution was withdrawn and transferred to microcap centrifuge tubes
containing 1 ml of chilled buffer; this mixture was immediately
centrifuged at 12,000 × g for 5 min at 4°C. The
pellet was washed once in 1 ml of buffer at 4°C and resuspended in 1 ml of 0.1 M glycine hydrochloride (pH 3.0) and incubated at 20°C
overnight to lyse the bacterial cells. The suspension was then
centrifuged twice at 20°C for 5 min to remove any cell debris. The
concentration of the antibiotic was estimated by HPLC analysis. A
Hewlett-Packard model 1050 system (Milan, Italy) equipped with a
Hewlett-Packard 1046A fluorescence detector was used for liquid
chromatography. A Rheodyne model 7125 loading injection valve (Cotati,
Calif.) with a 100-µl loop was also used. The chromatographic
apparatus was connected to a Hewlett-Packard model 3395 reporting
integrator. The excitation and emission wavelengths were 286 and 452 nm, respectively. Chromatographic separation was carried out at room
temperature with a Hypersil C18 cartridge column
(5-µm-particle-size column, 125 by 4.6 mm [inner diameter];
Alltech, Milan, Italy), equipped with a direct-connect guard column.
The eluent mixture consisted of acetonitrile and pH 4.5 buffer mixture
(40:60 [vol/vol]). The mobile phase flow rate was 1 ml/min with a
mean pressure of 85 atm. The eluent was filtered through a
0.2-µm-pore-size Teflon membrane (Spartan-3; Schleicher & Schuell,
Keene, N.H.) and deaerated by ultrasonication prior to use, and
Enoxacin was used as internal standard. The HPLC assay reproducibility
was evaluated by repetitive analysis of bacterial cell suspensions
spiked with a known amount of ofloxacin. The within-day reproducibility
was 99.1% ± 1.7% (assay accuracy ± relative standard
deviation; n = 9). The day-to-day reproducibility was
98.3% ± 2.5%. The lower detection limit of ofloxacin in biological samples was 3 ng/ml with a signal/noise ratio of 4:1. In the
chromatographic analysis, no interference was observed from the other
components present in the various samples. The results are expressed as
nanograms of drug per milligram of protein (2, 15, 34).
 |
RESULTS AND DISCUSSION |
The mean size of a colloidal drug carrier is an important
requisite that can influence the delivery device's biological
effectiveness (26, 42). In order to obtain liposome
colloidal suspensions with a reduced mean size, the extrusion through
polycarbonate filters was carried out. Before extrusion, the various
liposome suspensions were characterized by liposomes with a mean
diameter greater than 1.5 µm and a polydispersity index value of
~0.8, showing the presence of large vesicles with a very large size distribution. The extrusion procedure provided liposome suspensions with vesicles with a mean diameter of ~190 nm, as evidenced by light-scattering experiments (Fig. 1).
This procedure also allowed the formation of liposome suspensions with
a very narrow size distribution having a polydispersity index of 0.01. The extrusion process also determined a significative reduction of the
number of lamellae per vesicle, as shown by 31P-NMR
spectroscopy (data not reported). In fact, the hydration of the lipid
films, followed by freezing and thawing, led to the formation of
multilamellar systems with a mean of 11 lamellae per vesicle; after the
extrusion, the number of lamellae per vesicle was reduced to 2. Thus, a
conversion from multilamellar to oligolamellar systems was achieved.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 1.
Size distribution of oligolamellar liposome suspension
(MC-Chol-DP, 4:3:4 molar ratio) obtained by extrusion through
polycarbonate filters (200-nm pore size). The sample was diluted to
achieve the most suitable optical density for light-scattering
analysis. The distribution function was determined by the Laplace
inversion transform. Similar results were obtained with other liposome
colloidal suspensions.
|
|
Before extrusion, large multilamellar vesicles were submitted to a
freeze-and-thaw process to achieve a high drug-entrapping efficiency
within liposomes (33). As reported in Table
1, the freeze-and-thaw procedure elicited
an increase of ofloxacin loading capacity within various formulations
of about three times compared to that of simple large multilamellar
vesicles. It is noteworthy that the extrusion determined no variation
of drug content and encapsulation capacity values of frozen and
thawed liposomes. Enhanced colloidal properties and high
drug carrier capacity represent two important parameters for an
effective drug delivery system to be proposed in antibacterial
chemotherapy.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Encapsulation parameters of the various liposome
formulations as a function of the preparation procedure and lipid
matrix compositiona
|
|
Liposome formulations which are able to deliver their content directly
into the cell cytoplasm by fusion with the plasma membrane could have a
special advantage in terms of intracellular transport and hence
antibacterial effectiveness. For this reason, the fusogenic properties
of the various liposome formulations with respect to a bacterial outer
membrane model were investigated by evaluating the increase of the
fluorescence intensity at 492 and 554 nm due to the
Tb(DPA)33
complex, which was formed following
the fusion between Tb(III)-loaded MC-PG-LPS (5:3:2 molar ratio)
membranes and DPA-loaded phospholipid mixture membranes.
Membrane fusion leads to the formation of the
Tb(DPA)33
complex, resulting in an increase
in the fluorescence intensity of both bands as a function of the
incubation time. As shown in Fig. 2, a
noticeable increase in the fluorescence emission intensity at 492 and
554 nm was observed for liposomes presenting PS in their lipid
composition. The other liposome formulations showed a lower
fluorescence intensity increase (Fig. 2).

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 2.
Fluorescence intensity profiles at 492 nm of the various
liposome formulations. Symbols: , MC-Chol-PS (4:3:4 molar ratio);
, MC-Chol-DP (4:3:4 molar ratio); , MC-Chol-PA (4:3:4 molar
ratio); , MC-Chol-PE (4:3:4 molar ratio). The experiments were
carried out at 37 ± 0.05°C (mean ± standard deviation).
|
|
The formation of the highly fluorescent
Tb(DPA)33
complex can be triggered not only
by vesicle fusion but also by molecular transfer through the bulk
aqueous phase or upon contact release. This possibility was evaluated
by physically separating the MC-PG-LPS (5:3:2 molar ratio) bacterial
outer membrane model from the various liposome formulations with a
dialysis membrane. This experiment showed that the molecular transfer
phenomenon also took place to a certain extent for all liposome
formulations (Fig. 3). Only 13% of the
fluorescence intensity increase can be attributed to a molecular
transfer rather than to a fusion process for liposomes containing PS.
For other formulations, taking into account data reported in Fig. 2 and
3, the molecular transfer phenomenon seemed to be the main process
determining the fluorescence increase.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
Fluorescence intensity profiles at 492 nm of the various
liposome formulations as a function of time. The liposome formulations
were separated from the bacterial outer membrane model made up of
MC-PG-LPS (5:3:2 molar ratio) by means of a dialysis bag (molecular
weight cutoff, 25,000). Symbols: , MC-Chol-PS (4:3:4 molar ratio);
, MC-Chol-DP (4:3:4 molar ratio); , MC-Chol-PA (4:3:4 molar
ratio); , MC-Chol-PE (4:3:4 molar ratio). The experiments were
carried out at 37 ± 0.05°C (mean ± standard deviation).
|
|
The in vitro susceptibilities to free drug and ofloxacin-loaded
liposomes are shown for comparison. Ofloxacin-loaded liposomes yielded
MICs that were different from those obtained with the free drug (Table
2). Differences were observed between the
four liposome formulations. Unilamellar liposomes made up of MC-Chol-PS and MC-Chol-DP yielded MICs lower than those obtained with the free
drug. In particular, a twofold MIC decrease was obtained with respect
to that for P. aeruginosa, while the highest MIC decrease
was achieved in the case of E. faecalis (16-fold decrease). MICs obtained with MC-Chol-PE and MC-Chol-PA matched those obtained with the free drug or were 1 dilution higher or lower. Free liposomes showed no activity against all the bacteria tested up to a
concentration 100 times higher than that used throughout our
experiments.
Our findings show that the liposome composition is an important
parameter that is able to influence the antibacterial effectiveness of
the drug-loaded delivery devices. The presence of a negatively charged
component able to interact with bacterial cell surfaces, i.e., PS and
DP, in the constitution of the liposome matrix seems to be a
fundamental requisite to ensure a certain improvement of the
antibacterial effectiveness (PE component is positively charged). In
fact, negatively charged phospholipids, such as PS and DP, can form
hydrogen bonds and/or ionic interactions with various components which
constitute the outer bacterial membranes, i.e., saccharide moieties of
various natures, phospholipids (phosphatidylglycerol and
diphytanoyl-phosphatidylcholine), glycosphingolipids,
lipopolysaccharides, and peptidoglycan (30, 31).
Furthermore, the liposome bilayer fluidity and fusogenic properties
seem to be other important factors in determining biological effectiveness. Fusogenic properties can cause the liposome carrier to
fuse with the bacterial outer membrane, thus delivering its content
into bacterial cells. Bilayer fluidity can be particularly important in
the case of gram-positive bacteria, which have the peptidoglycan
barrier hampering the direct contact with liposomes. Liposomes having a
bilayer membrane with a certain fluidity can release their content
after the interaction with the external peptidoglycan barrier, whereas
liposomes which have a rigid bilayer structure release their content
very slowly, thus being less effective against bacterial cells
(25, 52). In particular, the PA component presents a polar
head with a negative charge as well, but does not confer either a
certain fluidity as DP does or fusogenic properties to the bilayer
structure as PS does (13, 17, 28).
Liposome formulations made up of MC-Chol-PE and MC-Chol-PA were not
investigated against fresh isolates because of poor improvement of
antibacterial activity shown in the case of the reference strains assayed. The in vitro susceptibilities of 20 fresh isolates to both
MC-Chol-DP and MC-Chol-PS liposome formulations are shown in Table
3. Similarly to previous results obtained
with standard strains, MICs were lower than those obtained with the
free drug. Four- and eightfold improvements were gained with E. coli and S. aureus, respectively, and up to 32-fold
improvements were gained with E. faecalis. Differences were
observed between the two formulations, namely that MC-Chol-DP was more
active than MC-Chol-PS. In the case of P. aeruginosa, a
lower MIC improvement was obtained. In fact, the best MIC improvement
against P. aeruginosa was a fourfold decrease for the
MC-Chol-DP liposome mixture.
View this table:
[in this window]
[in a new window]
|
TABLE 3.
In vitro activity of different liposome formulations
containing ofloxacin against freshly isolated bacteria
|
|
Three different entrance routes have been proposed for fluoroquinolones
to penetrate cell envelopes of gram-negative bacteria: (i) the
hydrophilic pathway through porin channels (40), (ii) the
hydrophobic pathway through the membrane bilayer matrix
(27), and (iii) the self-promoted uptake pathway
(10). The first two entrance pathways seem to be influenced
by some drug properties, such as hydrophobicity and the size and
structure of fluoroquinolones (J. Pace, A. Bertasso, and N. H. Georgopadakou, Abstr. 91st Annu. Meet. Am. Soc. Microbiol. 1991, p. 16, 1991). Meanwhile, the self-promoted uptake route is based on the
displacement of divalent cations (mainly Mg2+ and
Ca2+) from the outer membrane lipopolysaccharides. How a
vesicular carrier (unilamellar liposomes) can influence the penetration of a fluoroquinolone agent (ofloxacin) has been investigated.
Accumulation of ofloxacin at a fixed concentration, both free and
liposome entrapped, by a strain of E. coli (ATCC 25922) and
a strain of P. aeruginosa (ATCC 27853) was examined. Owing to the lower MICs, only MC-Chol-DP liposomes were investigated. The
results of the accumulation are shown in Fig.
4 and 5. In E. coli strains, a gradual drug entry followed the rapid
phase of accumulation. Similar profiles were observed for P. aeruginosa. In this case, the accumulation time course was
extended up to 25 min due to the slower and lower ofloxacin
accumulation into P. aeruginosa (2). The liposome
formulations reached significantly (P < 0.001) higher
intracellular accumulations than the free drug with the two strains
tested.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 4.
Intrabacterial accumulation of ofloxacin-loaded
MC-Chol-DP (4:3:4 molar ratio) unilamellar liposomes within E. coli ATCC 25922 ( ) and E. coli ATCC 35218 ( )
versus the free drug (E. coli ATCC 35218 accumulation) ( )
as a function of time. Free drug accumulation within both E. coli strains was very similar (data not reported). The experiments
were carried out at 37°C. Each point represents the mean value of
five different experiments ± standard deviation.
|
|

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 5.
Intrabacterial accumulation of ofloxacin-loaded
MC-Chol-DP (4:3:4 molar ratio) unilamellar liposomes within P. aeruginosa ATCC 27853 ( ) versus the free drug ( ) as a
function of time. The experiments were carried out at 37°C. Each
point represents the mean value of five different experiments ± standard deviation.
|
|
These results can be due to the capability of the liposome carrier to
interact with the bacterial cell outer membranes, altering the
permeation conditions. In fact, liposomes presenting fusogenic properties, such as MC-Chol-PS vesicles, may fuse with the membrane, enhancing drug entry through the hydrophobic and/or self-promoted pathway. In fact, liposome fusion or vesicle-bacterial outer membrane phospholipid exchange may elicit an increase of disorder and fluidity of biological membrane bilayers, leading to greater membrane
permeability. No particular effect should be exerted by the liposome
carrier at the level of the porin entrance pathway, if for no other
reason than due to the fact that an alteration of the membrane
phospholipid matrix may trigger conformational changes of porin proteins.
Although ofloxacin bacterial outer membrane penetration and
accumulation should correlate to some extent with differences in
susceptibility, the latter is correlated not only to drug entrance (improved uptake) but also to the affinity with the drug to its target.
In fact, our results show that liposome formulations can contribute to
overcome bacterial resistance phenomena due to drug entrance
(impermeability) (9, 48) by ensuring higher intrabacterial ofloxacin levels, but cannot be useful to avoid and/or circumvent DNA
gyrase resistance (1, 24).
According to the literature (8), a susceptibility-drug
accumulation relationship has also been observed in the case of P. aeruginosa. Namely, P. aeruginosa presents a
poor outer membrane permeability (2), probably
due to the presence of water-filled channels in this bacteria, such as
porin F, that are substantially smaller than those of other
gram-negative bacteria (55). This fact determines a lower
permeability of hydrophilic antibiotics through the bacterial outer
membrane. This intrinsic resistance, previously attributed only to the
low permeability, is now recognized from the results of the synergy
between broadly specific drug efflux pumps and low outer membrane
permeability (39, 43, 50). Thus, an increased outer membrane
permeability due to the liposome formulation is likely to contribute to
the improved susceptibility of these organisms, as has been
demonstrated also for other colloidal drug carriers (15).
Therefore, any condition determining a concentration gradient towards
bacterial cell outer membranes could improve the drug permeation.
Liposomes, besides having a direct interaction with the bacterial cell
outer membrane, can also ensure "contact" and/or "juxtaproximal" release (38), that is, a massive drug
release close to the bacterial cell surface (both outer membrane and
peptidoglycan), allowing the formation of a drug concentration gradient
and hence a higher rate of entrance than that of the free drug. The
latter aspect is particularly important in the case of gram-positive bacteria, which present a peptidoglycan barrier that can hamper a
direct contact with the cytoplasmic membrane. In this case, liposomes
may interact with peptidoglycan and release ofloxacin, thus ensuring
drug entrance. This possibility seems to be the more probable
mechanism, rather than the liposome-bacterial membrane fusion, to
explain the ofloxacin-loaded liposome activity greater than that of the
free drug with respect to gram-positive bacteria (Table 3).
The initial step in the accumulation of fluoroquinolone
antimicrobial agents, i.e., binding to cell surface components
(7), is reduced by lowered pH and, under some
conditions, by divalent cations (10). Fluoroquinolones with
net charges (H2Q+, Q
)
are not soluble in membrane structures; thus, accumulation would depend
solely on the partition of the neutral forms (19, 43). Since
inner pH is stable, the penetrating activities of quinolones in this
model become simply a function of the outer pH. The uncharged species
HQ0 is the best candidate to mediate passive diffusion for
acidic quinolones, but the zwitterionic species (HQ+
) is
very likely to be implicated in transmembrane diffusion as well
(44). Therefore, considering these aspects and the fact that
fluoroquinolones cross the cytoplasmic membrane by simple diffusion,
ofloxacin-liposome encapsulation can also have the advantage of
ensuring higher rates of drug entrance into the periplasmic space
in spite of adverse environmental conditions (pH, presence of
divalent cations, and drug physicochemical characteristics) and/or forms of bacterial resistance due to reduced drug permeability.
In conclusion, liposome drug delivery systems with suitable lipid
compositions can improve the antibacterial effectiveness of loaded
fluoroquinolone drugs, due to (i) a greater drug penetration within
bacterial cells and (ii) protection against unfavorable environmental
conditions. Liposome colloidal suspensions could be a suitable tool to
improve selective drug delivery. In particular, liposomes can be used
for the treatment of infection involving the mononuclear phagocyte
systems, which take up colloidal carriers after systemic
administration. Other body sites can be reached by modulating liposome
size, lipid composition, and surface characteristics.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiological Sciences, University of Catania, Via Androne 81, I-95124 Catania, Italy. Phone: 39 095316038. Fax: 39 095312798. E-mail: furneri{at}mbox.unict.it.
 |
REFERENCES |
| 1.
|
Aoyama, H.,
K. Sato,
T. Fujii,
K. K. Fugimaki,
M. Inoue, and S. Mitsuhashi.
1988.
Purification of Citrobacter freundii DNA gyrase and inhibition of quinolones.
Antimicrob. Agents Chemother.
32:104-109[Abstract/Free Full Text].
|
| 2.
|
Asuquo, A. E., and L. J. V. Piddock.
1993.
Accumulation and killing of fifteen quinolones for Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa.
J. Antimicrob. Chemother.
31:865-880[Abstract/Free Full Text].
|
| 3.
|
Bakker-Woundenberg, I. A. J. M.,
A. F. Lokerse,
M. T. ten Kate,
P. M. B. Melissen,
W. van Vianen, and E. W. M. van Ettenn.
1993.
Liposomes as carriers of antimicrobial agents or immunomodulatory agents in the treatment of infections.
Eur. J. Clin. Microbiol. Infect. Dis.
12:61-67[CrossRef].
|
| 4.
|
Barela, T. D., and A. D. Sherry.
1976.
A simple, one-step fluorometric method for determination of nanomolar concentrations of terbium.
Anal. Biochem.
71:351-357[CrossRef][Medline].
|
| 5.
|
Benita, S.,
P. A. Poly,
F. Puisieux, and J. Delattre.
1984.
Radiopaque liposomes: effect of formulation conditions on encapsulation efficiency.
J. Pharm. Sci.
73:1751-1754[CrossRef][Medline].
|
| 6.
|
Berne, B., and R. Pecora.
1976.
Dynamic light scattering.
John Wiley and Sons, New York, N.Y.
|
| 7.
|
Bryan, L. E., and J. Bedard.
1991.
Impermeability to quinolones in Gram-positive and Gram-negative bacteria.
Eur. J. Clin. Microbiol. Infect. Dis.
10:232-239[CrossRef][Medline].
|
| 8.
|
Celesk, R. A., and N. J. Robillard.
1989.
Factors influencing the accumulation of ciprofloxacin in Pseudomonas aeruginosa.
Antimicrob. Agents Chemother.
33:1921-1926[Abstract/Free Full Text].
|
| 9.
|
Chamberland, S.,
A. S. Bayer,
T. Scholiaardt,
S. A. Wong, and L. E. Bryan.
1989.
Characterization of mechanisms of quinolone resistance in Pseudomonas aeruginosa strains isolated in vitro and in vivo during experimental endocarditis.
Antimicrob. Agents Chemother.
33:624-634[Abstract/Free Full Text].
|
| 10.
|
Chapman, J. S., and N. H. Georgopapadakou.
1988.
Routes of quinolone permeation in Escherichia coli.
Antimicrob. Agents Chemother.
32:438-442[Abstract/Free Full Text].
|
| 11.
|
Chu, B.
1974.
Laser light scattering.
Academic Press, New York, N.Y.
|
| 12.
|
Ferrero, L.,
B. Cameron, and J. Crouzet.
1995.
Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus.
Antimicrob. Agents Chemother.
39:1554-1558[Abstract].
|
| 13.
|
Fresta, M.,
A. Spadaro,
G. Cerniglia,
I. M. Ropero,
G. Puglisi, and P. M. Furneri.
1995.
Intracellular accumulation of ofloxacin-loaded liposomes in human synovial fibroblasts.
Antimicrob. Agents Chemother.
39:1372-1375[Abstract].
|
| 14.
|
Fresta, M.,
A. Villari,
G. Puglisi, and G. Cavallaro.
1993.
5-Fluorouracil various kinds of loaded liposomes: encapsulation efficiency, storage stability and fusogenic properties.
Int. J. Pharm.
99:146-157.
|
| 15.
|
Fresta, M.,
E. Wehrli, and G. Puglisi.
1995.
Enhanced therapeutic effect of cytidine-5I-diphosphate choline when associated with GM1 containing small liposomes as demonstrated in a rat ischemia model.
Pharm. Res.
12:1769-1774[CrossRef][Medline].
|
| 16.
|
Fresta, M.,
G. Puglisi,
G. Giammona,
G. Cavallaro,
N. Micali, and P. M. Furneri.
1995.
Pefloxacine mesilate- and ofloxacin-loaded polyethylcyanoacrylate nanoparticles: characterization of the colloidal drug carrier formulation.
J. Pharm. Sci.
84:895-902[CrossRef][Medline].
|
| 17.
|
Fresta, M.,
P. M. Furneri,
E. Mezzasalma,
V. M. Nicolosi, and G. Puglisi.
1996.
Correlation of trimethoprim and brodimoprim physicochemical and lipid membrane interaction properties with their accumulation in human neutrophils.
Antimicrob. Agents Chemother.
40:2865-2873[Abstract].
|
| 18.
|
Fresta, M.,
R. Chillemi,
S. Spampinato,
S. Sciuto, and G. Puglisi.
1999.
Liposomal delivery of a 30-Mer antisense oligodeoxynucleotide to inhibit proopiomelanocortin expression.
J. Pharm. Sci.
87:616-625[CrossRef].
|
| 19.
|
Furet, Y. X.,
J. Deshusses, and J. C. Pechere.
1992.
Transport of pefloxacin across the bacterial cytoplasmatic membrane in quinolone-susceptible Staphylococcus aureus.
Antimicrob. Agents Chemother.
36:2506-2511[Abstract/Free Full Text].
|
| 20.
|
Gimeno, C.,
J. Borja,
D. Navarro,
L. Valdes,
J. Garcia-Barbal, and J. Garcia-de-Lomas.
1998.
In vitro interaction between ofloxacin and cefotaxime against gram-positive and gram-negative bacteria involved in serious infections.
Chemotherapy
44:94-98[CrossRef][Medline].
|
| 21.
|
Goldstein, E. J.,
D. M. Citron,
M. Hudspeth,
S. H. Gerardo, and C. V. Merriam.
1998.
Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens.
J. Antimicrob. Chemother.
41:391-396[Abstract/Free Full Text].
|
| 22.
|
Gootz, T. D., and K. E. Brighty.
1996.
Fluoroquinolone antibacterials: SAR, mechanism of action, resistance, and clinical aspects.
Med. Res. Rev.
16:433-486[CrossRef][Medline].
|
| 23.
|
Guibert, J.,
M. D. Kitzis, and J. F. Acar.
1998.
Antibacterial activity of ofloxacin in urine for 4 days after a single oral dose of 400 mg.
Pathol. Biol.
46:656-660[Medline].
|
| 24.
|
Hirai, K.,
S. Suzue,
T. Irikura,
S. Iyobe, and S. Mitsuhashi.
1987.
Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa.
Antimicrob. Agents Chemother.
31:582-586[Abstract/Free Full Text].
|
| 25.
|
Ito, Y.,
H. Cai,
Y. Koizumi,
R. Hori,
M. Terao,
T. Kimura,
S. Takagi, and M. Tomohiro.
2000.
Effects of lipid composition on the transcorneal penetration of liposomes containing a potential anti-cancer agent, in the rabbit.
Biol. Pharm. Bull.
23:327-333[Medline].
|
| 26.
|
Karajgi, J.,
N. K. Jain, and S. P. Vyas.
1993.
Passive vectoring of a colloidal carrier system for sodium stibogluconate: preparation, characterization and performance evaluation.
J. Drug Target
1:197-206[Medline].
|
| 27.
|
Kotera, Y.,
M. Watanabe,
S. Yoshida,
M. Inoue, and S. Mitsuhashi.
1991.
Factors influencing the uptake of norfloxacin by Escherichia coli.
J. Antimicrob. Chemother.
27:733-739[Abstract/Free Full Text].
|
| 28.
|
La Rosa, C.,
D. Grasso,
M. Fresta,
C. Ventura, and G. Puglisi.
1992.
Phospholipid vesicles as drug delivery system. Part II. A study on kinetic fusion between vesicles containing CDP-choline and dipalmitoylphosphatidylcholine vesicles.
Thermochim. Acta
198:181-190[CrossRef].
|
| 29.
|
Lee, S.,
T. Park, and Y. Lee.
1998.
Structure-activity relationship of fluoroquinolone in Escherichia coli.
Arch. Pharm. Res.
21:106-112[Medline].
|
| 30.
|
Lohner, K., and E. J. Prenner.
1999.
Differential scanning calorimetry and X-ray diffraction studies of the specificity of the interaction of antimicrobial peptides with membrane-mimetic systems.
Biochim. Biophys. Acta
1462:141-156[Medline].
|
| 31.
|
Lohner, K.,
E. Straudegger,
E. J. Prenner,
R. N. Lewis,
M. Kriechbaum,
G. Degovics, and R. N. McElhaney.
1999.
Effect of staphylococcal -lysin on the thermotropic phase behavior and vesicle morphology of dimyristoylphosphatidylcholine lipid bilayer model membranes. Differential scanning calorimetric, 31P nuclear magnetic resonance and fourier transform infrared spectroscopic, and X-ray diffraction studies.
Biochemistry
38:16514-16528[CrossRef][Medline].
|
| 32.
|
Macek, J., and P. Ptacek.
1995.
Determination of ofloxacin in human plasma using high-performance liquid chromatography and fluorescence detection.
J. Chromatogr. B.
673:316-319[CrossRef][Medline].
|
| 33.
|
Mayer, L. D.,
M. J. Hope,
P. R. Cullis, and A. S. Janoff.
1985.
Solute distribution and trapping efficiencies in freeze-thawed multilamellar vesicles.
Biochim. Biophys. Acta
817:193-196[Medline].
|
| 34.
|
Mortimer, P. G. S., and L. J. V. Piddock.
1991.
A comparison of methods used for measuring the accumulation of quinolones by Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus.
J. Antimicrob. Chemother.
28:639-653[Abstract/Free Full Text].
|
| 35.
|
Müller, M.,
C. Meister, and H. Moor.
1980.
Freezing in a propane jet and its application in freeze-fracturing.
Mikroskopie
36:129-140[Medline].
|
| 36.
|
Naber, K. G.,
M. Well,
K. Hollauer,
D. Kirchbauer, and W. Witte.
1998.
In vitro activity of enoxacin versus ciprofloxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
Chemotherapy
44:77-84[CrossRef][Medline].
|
| 37.
|
National Committee for Clinical Laboratory Standards.
2000.
Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically-5th ed. Approved standard M7-A5.
National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 38.
|
New, R. R. C.,
C. D. V. Black,
R. J. Parker,
A. Puri, and G. L. Scherphof.
1990.
Liposomes in biological systems, p. 221-252.
In
R. R. C. New (ed.), Liposomes, a practical approach. I.R.L. Press-Oxford University Press, New York, N.Y.
|
| 39.
|
Nikaido, H.
1989.
Outer membrane barrier as mechanisms of antimicrobial resistance.
Antimicrob. Agents Chemother.
33:1831-1836[Free Full Text].
|
| 40.
|
Nikaido, H., and M. Vaara.
1985.
Molecular basis of bacterial outer membrane permeability.
Microbiol. Rev.
49:1-32[Free Full Text].
|
| 41.
|
Onrust, S. V.,
H. M. Lamb, and J. A. Balfour.
1998.
Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.
Drugs
56:895-928[CrossRef][Medline].
|
| 42.
|
Perez-Soler, R., and A. R. Khokhar.
1992.
Lipophilic cisplatin analogues entrapped in liposomes: role of intraliposomal drug activation in biological activity.
Cancer Res.
52:6341-6347[Abstract/Free Full Text].
|
| 43.
|
Piddock, L. J.
1999.
Mechanisms of fluoroquinolone resistance: an update 1994-1998.
Drugs
58:11-18.
|
| 44.
|
Piddock, L. J.,
Y. F. Jin,
V. Ricci, and A. E. Asuquo.
1999.
Quinolone accumulation by Pseudomonas aeruginosa, Staphylococcus and Escherichia coli.
J. Antimicrob. Chemother.
43:61-70[Abstract/Free Full Text].
|
| 45.
|
Puglisi, G.,
M. Fresta,
G. Mazzone,
P. M. Furneri, and G. Tempera.
1995.
Formulation parameters of fluoroquinolones-loaded liposomes and in vitro antimicrobial activity.
Int. J. Pharm.
118:65-76[CrossRef].
|
| 46.
|
Ramon, M. S.,
E. Canton,
J. Peman,
A. Pastor, and J. P. Martinez.
1999.
Mechanisms of action of quinolones against staphylococci and relationship with their in vitro bactericidal activity.
Chemotherapy
45:175-182[CrossRef][Medline].
|
| 47.
|
Richardson, V. J.
1983.
Liposomes in antimicrobial chemotherapy.
J. Antimicrob. Chemother.
12:532-534[Free Full Text].
|
| 48.
|
Robillard, N. J., and A. L. Scarpa.
1988.
Genetic and physiological characterization of ciprofloxacin resistance in Pseudomonas aeruginosa PAO.
Antimicrob. Agents Chemother.
32:535-539[Abstract/Free Full Text].
|
| 49.
|
Schwartz, M. A., and H. M. McConnell.
1978.
Surface areas of lipid membranes.
Biochemistry
17:837-840[CrossRef][Medline].
|
| 50.
|
Skrikumar, R.,
T. Kon,
N. Gotoh, and K. Poole.
1998.
Expression of Pseudomonas aeruginosa multidrug efflux pumps MexA-MexB-OprM and MexC-MexD-OprJ in a multidrug-sensitive Escherichia coli strain.
Antimicrob. Agents Chemother.
42:65-71[Abstract/Free Full Text].
|
| 51.
|
Tas, J., and G. J. Westerneng.
1981.
Fundamental aspects of the interaction of propidium diiodide with nuclei acids studied in a model system of polyacrylamide films.
J. Histochem. Cytochem.
29:929-936[Abstract].
|
| 52.
|
Thierry, A. R., and A. Dritschilo.
1992.
Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity.
Nucleic Acids Res.
20:5691-5698[Abstract/Free Full Text].
|
| 53.
|
Wiese, A.,
M. Munstermann,
T. Gutsmann,
B. Lindner,
K. Kawahara,
U. Zahringer, and U. Seydel.
1998.
Molecular mechanisms of polymyxin B-membrane interactions: direct correlation between surface charge density and self-promoted transport.
J. Membr. Biol.
15:127-138.
|
| 54.
|
Wilschut, J.,
R. F. Duzgunes, and D. Papahadjopoulos.
1980.
Studies on the mechanism of membrane fusion: kinetics of calcium ion induced fusion of phosphatidylserine vesicles followed by a new assay for mixing of aqueous vesicle contents.
Biochemistry
19:6011-6021[CrossRef][Medline].
|
| 55.
|
Woodruff, W. A.,
T. R. Parr, Jr.,
R. E. W. Hancock,
L. F. Hanne,
T. I. Nicas, and B. H. Iglewski.
1986.
Expression in Escherichia coli and function in Pseudomonas aeruginosa outer membrane porin protein F.
J. Bacteriol.
167:473-479[Abstract/Free Full Text].
|
Antimicrobial Agents and Chemotherapy, September 2000, p. 2458-2464, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Kadry, A. A., Al-Suwayeh, S. A., Abd-Allah, A. R. A., Bayomi, M. A.
(2004). Treatment of experimental osteomyelitis by liposomal antibiotics. J Antimicrob Chemother
54: 1103-1108
[Abstract]
[Full Text]